ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients

American Journal of Hematology

Volumn 85, Issue 7, 2010, Pages 494-498

  Zanotti, Roberta ^a   Frattini, Franzesco ^a   Ghia, Paolo ^b   Visco, Carlo ^c   Zamò, Alberto ^d   Perbellini, Omar ^a   Stella, Stefania ^e   Facco, Monica ^f   Giaretta, Ilaria ^c   Chilosi, Marco ^d   Pizzolo, Giovanni ^a   Ambrosetti, Achille ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; PROTEIN KINASE ZAP 70; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOIMMUNE CYTOPENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BONE MARROW BIOPSY; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PURE RED CELL ANEMIA; RISK FACTOR; BLOOD; HEMATOLOGIC DISEASE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN VARIABLE REGION; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; AUTOIMMUNE DISEASES; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RED-CELL APLASIA, PURE; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77954948781     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21737     Document Type: Article

References (28)

1. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792. (Pubitemid 30235886)
2. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003;74:1-8.
3. Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab-incidence and predictors. Br J Haematol 2007;136:800-805. (Pubitemid 46348418)
4. Dearden C, Wade R, Else M, et al;UK National Cancer Research Institute (NCRI); Haematological Oncology Clinical Studies Group; NCRI CLL Working Group. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-1826.
5. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008;141:615-621. (Pubitemid 351667621)
6. Visco C, Ruggeri M, Evangelista LM, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:1110-1116. (Pubitemid 351213389)
7. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008:450-456.
8. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-239.
9. Barcellini W, Capalbo S, Agostinelli RM, et al;GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006;91:1689-1692.
10. Catovsky D, Richards S, Matutes E, et al;UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007;370:230-239.
11. Di Raimondo F, Giustolisi R, Cacciola E, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993;11:63-68. (Pubitemid 23287052)
12. Weiss RB, Freiman J, Kweder SL, et al. Haemolytic anaemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16:1885-1889. (Pubitemid 28234736)
13. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-1775. (Pubitemid 36514707)
14. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105-111. (Pubitemid 38068326)
15. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893-901.
16. Admirand JH, Rassidakis GZ, Abruzzo LV, et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Modern Pathology 2004;17:954-961.
17. Zanotti R, Ambrosetti A, Lestani M, et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia 2007;21:102-109.
18. Sabattini E, Orduz R, Campidelli C, et al. B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: Role of ZAP70 determination on bone marrow biopsy specimens. J Clin Pathol 2007;60:627-632.
19. Hallek M, Cheson BD, Catovsky D, et al;International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-5456.
20. Rozman C, Montserrat E, Rodríguez-Fernández JM, et al. Bone marrow histologic pattern - the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 1984;64:642-648.
21. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003;101:1262-1269.
22. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.
23. Duek A, Shvidel L, Braester A, Berrebi A. Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J 2006;8:828.
24. Letestu R, Rawstron A, Ghia P, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom 2006;70:309-314.
25. Gachard N, Salviat A, Boutet C, et al; GEIL. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Haematologica 2008;93:215-223.
26. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:1923-1930.
27. Visco C, Giaretta I, Ruggeri M, et al. Un-mutated IgVH in chronic lymphocytic leukemia is associated with a higher risk of immune thrombocytopenia. Leukemia 2007;21:1092-1093.
28. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukaemia by malignant B cells. Blood 2005;105:2007-2015.